Prostate-specific antigen in the early detection of prostate cancer

Thompson, Ian M.; Ankerst, Donna P.
June 2007
CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1853
Academic Journal
Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer. Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer. Often thought to be dichotomous (i.e., either normal or elevated), PSA measurements actually reflect cancer risk, with the risks of cancer and of aggressive cancer increasing with the level of PSA. The recently developed risk calculator from the Prostate Cancer Prevention Trial, which integrates family history of prostate cancer, digital rectal examination findings, PSA test result, age, ethnicity, and history of a prior prostate biopsy with a negative result, allows clinicians to assess a patient's individual risk of cancer. This risk should be examined in the context of a patient's life expectancy and comorbidity as well as his concern about the possibility of prostate cancer. The terms ‘normal’ and ‘elevated’ as descriptors of PSA results should be abandoned.


Related Articles

  • Düşük prostat spesifik antijen deÄŸeri olan hastalara yapılan transrektal prostat biyopsi sonuçları. Bodakçi, Mehmet Nuri; Bozkurt, Yaşar; Atar, Murat; Hatipoğlu, Namık Kemal; Penbegül, Necmettin; Söylemez, Haluk; Sancaktutar, Ahmet Ali; Yıldırım, Kadir // Dicle Medical Journal / Dicle Tip Dergisi;2012, Vol. 39 Issue 2, p238 

    Objectives: The aim of this study is to evaluate the results of prostate biopsy of patients who had the prostatespecific antigen (PSA) levels below 4 ng/ml. Material and methods: The medical records of 63 patients who underwent transrectal prostate biopsy, between January 2005 and December 2011,...

  • PSA Failure Following Definitive Treatment of Prostate Cancer Having Biopsy Gleason Score 7 With Tertiary Grade 5. Patel, Abhijit A.; Chen, Ming-Hui; Renshaw, Andrew A.; D'Amico, Anthony V. // JAMA: Journal of the American Medical Association;10/3/2007, Vol. 298 Issue 13, p1533 

    This article presents the findings of a study of the Gleason score system which is designed to grade cancer of the prostate based on patterns on the prostatic glands. The system assigns a score from 1 to 5 to the most dominant pattern and to the second most prevalent pattern. The two grades are...

  • Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer. Patel, H. D.; Feng, Z.; Landis, P. // Reviews in Urology;2014, Vol. 16 Issue 3, p155 

    The article discusses a study which examines the potential of prostate-specific antigen velocity (PSAV) risk count to help monitor patients on active surveillance. Findings reveal that higher PSAV risk count was significantly linked with biopsy progression in the primary analysis, while on...

  • Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Sang Jin Kim; Tae Yoong Jeong; Dae Seon Yoo; Jinsung Park; Seok Cho; Seok Ho Kang; Sang Hyub Lee; Seung Hyun Jeon; Tchun Yong Lee; Sung Yul Park // Yonsei Medical Journal;Nov2015, Vol. 56 Issue 6, p1492 

    Purpose: To predict the malignant potential of prostate cancer (PCa) according to prostate-specific antigen velocity (PSAV), PSA density (PSAD), free/total PSA ratio (%fPSA), and digital rectal examination (DRE). Materials and Methods: From January 2009 to December 2012, 548 adult male patients...

  • Does the Time From Biopsy to Radical Prostatectomy Affect Gleason Score Upgrading in Patients With Clinical T1c Prostate Cancer? Eroglu, Muzaffer; Doluoglu, Omer Gokhan; Sarici, Hasmet; Telli, Onur; Ozgur, Berat Cem; Bozkurt, Selen // Korean Journal of Urology;Jun2014, Vol. 55 Issue 6, p395 

    Purpose: It is debated whether treatment delay worsens oncologic results in localized prostate cancer (PCa). Few studies have focused on the role of a delay between the time of biopsy and the time of surgery. Thus, we aimed to investigate the effect of the time period between biopsy and surgery...

  • PCA3: Predictive performance superior to PSA, fPSA. Guttman, Cheryl // Urology Times;10/1/2009, Vol. 37 Issue 11, p22 

    The article discusses the diagnostic and prognostic potential of prostate cancer antigen 3(PCA3), a molecular urine assay for prostate cancer. A study presented at the American Urological Association annual meeting held in Chicago, Illinois found that the combination of PCA3, free...

  • Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Thompson, Ian M.; Ankerst, Donna Pauler; Chen Chi; Goodman, Phyllis J.; Tangen, Catherine M.; Lucia, M. Scott; Ziding Feng; Parnes, Howard L.; Coltman Jr., Charles A. // JNCI: Journal of the National Cancer Institute;4/19/2006, Vol. 98 Issue 8, p529 

    Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who...

  • High PSA Not Always a Negative Outcome Predictor.  // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p10 

    The article reports that prostate cancer patients who have high prostate-specific antigen (PSA) levels are not always a negative outcome predictor.

  • Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates. Bratt, Ola; Adolfsson, Jan; Bill-Axelson, Anna; Holmberg, Lars; Lambe, Mats; Stattin, Pär; Garmo, Hans // JNCI: Journal of the National Cancer Institute;Sep2010, Vol. 102 Issue 17, p1336 

    Background Family history is a strong risk factor for prostate cancer. The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. Methods Data were from the nationwide population-based...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics